iBio: IBIO-610 primate study shows 9.6% lower fat
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
iBio, Inc. (IBIO) reported extended preclinical results for its long-acting Activin E-targeting antibody IBIO-610 in obese non-human primates, with observations through 28 weeks. The study included 5 animals receiving IBIO-610 and 6 receiving vehicle. At week 28, the IBIO-610 group showed a 2.3% reduction in body weight relative to vehicle. At week 24, total fat was 9.6% lower, abdominal subcutaneous fat 16.6% lower and visceral fat 10.96% lower relative to vehicle; lean mass was generally maintained. Active Activin E was nearly completely suppressed through week 28.
In separate preclinical work, an antibody-peptide fusion selectively bound and activated amylin receptors 1 and 3, with minimal binding to or activation of the calcitonin receptor alone. A single-dose study in lean rats found reduced food intake over 24 hours versus vehicle. The amylin data are to be presented at PEGS Europe 2026 and the Amylin-Based Therapeutics Summit; iBio plans further preclinical studies in diet-induced obesity models.
8-K Event Classification
Key Figures
Key Terms
Activin E-targeting antibody medical
non-human primate (NHP) medical
amylin receptor agonist medical
antibody-peptide fusion technical
calcitonin receptor medical
in vitro medical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did IBIO-610 show in iBio's primate study?
What did iBio's amylin program show?
When will iBio present its amylin data?
AI-generated analysis. How Rhea-AI works. Not financial advice.